Clinical trial
A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared…
NCT00451178 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00451178 |
|---|---|
| Title | A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only |
| Official title | An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin Versus R-CHOP in the First-Line Treatment of Patients With Intermediate and High-Risk Diffuse Large B-Cell Lymphoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | enzastaurin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone |
| Enrollment | 101 |
| Start date | May 1, 2007 |
| Primary completion | Feb 1, 2012 |
| Completion | Jan 1, 2013 |
| First posted | Mar 23, 2007 |
| Last update posted | Jul 21, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: